The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic ...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

Shares of Oculis climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy ...

Oculis (OCS) stock jumps as the FDA grants Breakthrough Therapy designation for its eye disease drug Privosegtor targeted at ...

Please provide your email address to receive an email when new articles are posted on . One physician said intravenous corticosteroids are useful for treating optic neuritis. Another argued ...

For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging ...

Your optic nerve is important as it is essential to our sight. The optic nerve’s function is to transmit information that we see and what is formed on our retina ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

Optic neuritis is acute inflammation of the optic nerve. Optic nerve is the nerve connecting the eye to the brain. It carries the visual signals from the retina to the brain where it is received and ...